HEPATOCELLULAR CARCINOMA

This study tested whether adding an experimental drug called SOT101 to an existing immunotherapy (pembrolizumab) could help control advanced cancers that had stopped responding to other treatments. It involved 166 adults with specific advanced solid tumors, including lung, colore…

This study tested whether combining three existing drugs—nivolumab (an immunotherapy), tadalafil (a blood pressure/erectile dysfunction drug), and oral vancomycin (an antibiotic)—could shrink advanced liver cancers. It was for adults whose liver cancer (either starting in the liv…

This study tested a computer system called BioTraceIO 360 designed to help doctors plan, monitor, and check liver tumor ablation procedures. Ablation uses heat to destroy cancer cells. The tool aimed to give doctors better guidance on where to place the treatment probe and more c…

This study tested whether adding one of two experimental drugs to a standard immunotherapy (nivolumab) could shrink tumors better than the standard drug alone in people with advanced liver cancer. It was a Phase 2 trial that enrolled a small number of patients before being termin…

This study aimed to find out which initial treatment works better for people with a specific stage of liver cancer that is too large for surgery but hasn't spread. It directly compared a two-drug immunotherapy combination (atezolizumab and bevacizumab) against localized treatment…

This early-stage study aimed to find a safe dose of a new drug called HFB301001 for adults with advanced cancers that had stopped responding to standard treatments. It involved 31 patients with cancers like sarcoma, kidney, liver, and melanoma. The trial was designed to test incr…

This early-stage study tested a new drug called SD-101, delivered directly into the liver's main artery, for people with advanced liver cancer. It aimed to see if combining this local treatment with standard immunotherapy drugs was safe and could help control the cancer. The tria…

This early-stage study tested a new drug called OC-001, both by itself and combined with an existing immunotherapy drug, in people with various advanced cancers that had stopped responding to standard treatments. The main goal was to check the safety of the drug and see how the b…

This study aimed to see if adding a specific type of chemotherapy directly into the liver's blood vessels (HAIC) before a standard artery-blocking treatment (TACE) and a targeted drug (donafenib) works better than just TACE plus the drug. It was for people with a specific advance…

This early-stage trial tested a new treatment for advanced liver cancer. Doctors took a patient's own immune cells, modified them in a lab to better target cancer, and then put them back into the patient. The main goal was to find a safe dose, but the study was stopped early by t…

This study tested if adding a novel electromagnetic field treatment, delivered through the mouth, could improve outcomes for people with advanced liver cancer when used with the drug regorafenib. It aimed to see if this combination could help control the cancer longer than regora…

This study tested whether combining two technologies could help doctors get better samples during liver biopsies for suspected cancer. Participants received a fluorescent dye and had their biopsy guided by a medical 'GPS' tracking system. The goal was to see if this combination c…

This study created a registry to collect and store tissue and blood samples from patients undergoing surgery or biopsy for liver or bile duct tumors. The samples are used for future research to better understand these cancers and develop new treatments. The study enrolled 1,000 p…

This study tested a special type of scan to see if it could accurately measure how well the liver is working in patients with liver cancer. The goal was to see if tracking liver function before, during, and after standard treatments like radiation or surgery could help doctors pl…

This study aimed to find a way to predict which patients with advanced liver cancer would benefit from a specific immunotherapy drug combination. Researchers planned to check patients' blood for certain immune cells before and after starting treatment to see if those cells could …